Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.
Nat Commun. 2024 Oct 23;15(1):9144. doi: 10.1038/s41467-024-53143-2.
Oral corticosteroids represents the most prevalent treatment for idiopathic granulomatous mastitis. Ductal lavage with triamcinolone acetonide and antibiotics followed by observation (DL-OBS) has emerged as a novel strategy, but a comparison of them remains lacking. Here in this multicenter, open-label, non-inferiority, randomized trial (ClinicalTrials.gov identifier: NCT03724903), we assigned 140 patients to oral corticosteroids (N = 71) and DL-OBS (N = 69), stratified by baseline M-score. The primary outcome is complete Clinical Response rate at 1 year. The non-inferiority margin is -15%. The primary outcome is 85.5% in DL-OBS and 87.3% in oral corticosteroids (difference: -1.8%; 95%CI, 13.2 to 9.5; P = .01) in intention-to-treat population, and 92.6% vs 98.2% (difference -5.6%; 95%CI -13.4 to 2.2; P = .01) in per-protocol population, respectively. The most common (>15%) adverse events were Cushingoid, epigastric pain and arthralgia in oral corticosteroids, and irregular menstruation in DL-OBS, respectively. Here, we report that DL-OBS shows similar efficacy to oral corticosteroids but with better safety profile.
口服皮质类固醇是特发性肉芽肿性乳腺炎最常用的治疗方法。曲安奈德和抗生素的乳管灌洗加观察(DL-OBS)已成为一种新的策略,但两者的比较仍缺乏。在此项多中心、开放标签、非劣效性、随机试验(ClinicalTrials.gov 标识符:NCT03724903)中,我们根据基线 M 评分将 140 名患者分为口服皮质类固醇组(N = 71)和 DL-OBS 组(N = 69)。主要结局是 1 年时完全临床缓解率。非劣效性边界为-15%。DL-OBS 的主要结局为 85.5%,口服皮质类固醇为 87.3%(差异:-1.8%;95%CI,13.2 至 9.5;P = 0.01),意向治疗人群;在符合方案人群中,分别为 92.6%和 98.2%(差异-5.6%;95%CI-13.4 至 2.2;P = 0.01)。最常见(>15%)的不良事件是口服皮质类固醇的库欣样、上腹痛和关节痛,以及 DL-OBS 的月经不规则。在这里,我们报告 DL-OBS 显示出与口服皮质类固醇相似的疗效,但安全性更好。